SCHEMBL1237597

SCHEMBL1237597

CC12CCC3c4ccc(O[Si](C)(C)C(C)(C)C)cc4CCC3C1CC/C2=C\C#N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 7/20 0.49
LMNA P02545 4/20 0.49
HSD17B1 P14061 3/20 0.49
MAPT P10636 2/20 0.49
RECQL P46063 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ESR1 P03372 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ESR2 Q92731 2/20 0.46
ABCC4 O15439 1/20 0.46
CYP2C9 P11712 1/20 0.46
ABCC1 P33527 1/20 0.46
SLCO1B1 Q9Y6L6 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA9 Q16790 1/20 0.46
ALDH1A1 P00352 1/20 0.44
HSD17B10 Q99714 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1237598 1.00 STS (0.49) STSLMNAHSD17B1MAPTRECQL
SCHEMBL8409267 0.87 STS (0.51) STSLMNAHSD17B1MAPTRECQL
SCHEMBL1656763 0.86 STS (0.50) STSLMNAHSD17B1MAPTRECQL
SCHEMBL7060058 0.86 STS (0.50) STSLMNAHSD17B1MAPTRECQL
SCHEMBL1236173 0.85 STS (0.49) STSLMNAHSD17B1MAPTRECQL
SCHEMBL12888961 0.85 STS (0.49) STSLMNAHSD17B1MAPTRECQL
SCHEMBL1659350 0.85 STS (0.49) STSLMNAHSD17B1MAPTRECQL
SCHEMBL1236171 0.85 STS (0.49) STSLMNAHSD17B1MAPTRECQL
SCHEMBL1657651 0.85 KDM4E (0.52) STSLMNAHSD17B1MAPTRECQL
SCHEMBL12888988 0.84 STS (0.47) STSLMNAHSD17B1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893284-B2 Oestrogen derivatives as inhibitors of steroid sulphatase STERIX LIMITED (GB) 2011-02-22 US disclosed
EP-1608671-B1 OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE STERIX LTD (GB) 2010-01-06 EP disclosed
US-20060094696-A1 Oestrogen derivatives as inhibitors of steroid sulphatase STERIX LIMITED (GB) 2006-05-04 US disclosed
EP-1608671-A1 OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE Sterix Limited (GB) 2005-12-28 EP disclosed
WO-2004085459-A1 OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE STERIX LIMITED (GB) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094696-A1 Oestrogen derivatives as inhibitors of steroid sulphatase HSD17B11, ESRRA, ESRRB STS 5/4885LMNA 4082/4885HSD17B1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.